BioGaia’s results for the third quarter to exceed market expectations

(Figures in the brackets refer to the same period the previous year)

During the third quarter of 2023, BioGaia's sales have been impacted by increased demand in EMEA, the Americas and APAC. The sales in EMEA were positively affected by quarterly variations for individual orders.

For the third quarter, sales are preliminarily estimated at SEK 318 million (258), an increase of 23% (excluding foreign exchange effects, 17%). The operating profit for the third quarter is preliminarily estimated at SEK 120 million (94), an increase of 28%.

BioGaia publishes the interim report for the third quarter 2023 on Friday, October 20, 2023, at 08:00 a.m. CEST, followed by an audiocast at 09:30 a.m. CEST.

Follow us:
Subscribe to BioGaia press releases here
LinkedIn here

Alexander Kotsinas, CFO
Email: [email protected]
Phone: +46 735 00 11 11

Mikaela Idermark Stern, Corporate Communications
Email: [email protected]
Phone: +46 730 95 61 50

About BioGaia AB
BioGaia is an innovative Swedish healthcare company that develops, markets, and sells probiotic products with documented health benefits. The products are sold through distribution partners or through our own distribution in more than 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm.

This disclosure contains information that BioGaia is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact persons set out above, at 10:00 p.m. CEST on October 16, 2023.